Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP21279 vs Sinemet in Parkinson's Disease
NCT01171313Phase 2Completed
- Sponsor
- XenoPort, Inc.
- Start
- Jul 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of XP21279 in Parkinson's disease (PD) (4 arms), sponsored by XenoPort, Inc. Primary endpoint: Change from Baseline in mean daily 'off' time at 2 weeks. Started Jul 2010; status: completed.
02
Drugs
XP21279
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01171313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171313.